Guidelines for Adult Immunisation

Available Vaccines

Diphtheria

Introduction

Diphtheria is an acute, respiratory infection caused by Corynebacterium diphtheriae, a gram-positive bacterium. The causative organism produces a potent exotoxin responsible for localised tissue destruction and formation of pseudomembrane in the upper respiratory tract. While the organism itself is rarely invasive, the exotoxin produced by toxigenic strains can exert both local and systemic effects. Haematogenous dissemination of the toxin may lead to serious complications, such as myocarditis and neuritis. Pharyngeal diphtheria, the most common manifestation, can result in acute and potentially life-threatening airway obstruction.

The disease is transmitted primarily through respiratory droplets and by direct contact with skin lesions or contaminated objects. Infection most often occurs following close contact with symptomatic patients or asymptomatic carriers. Notably, individuals with natural or vaccine-induced immunity may still harbour the organism and contribute to its spread.

In Malaysia, diphtheria incidence declined markedly after the introduction of routine childhood immunisation. Since 2016, diphtheria cases in Malaysia peaked and later declined, reaching their lowest during the COVID-19 pandemic. However, numbers began to rise again after 2022, showing a continuing upward trend.

Table 6.1 Vaccines Registered in Malaysia

Note:

  • The pertussis vaccine is available in an acellular form, combined with diphtheria and tetanus vaccines.
  • Tdap is recommended for adolescents and adults and contains lower doses of diphtheria and pertussis compared with the children’s DTaP.
  • Uppercase letters (T) indicate full-strength components; lowercase “d” and “p” indicate reduced doses. The “a” in Tdap stands for acellular, meaning it uses parts of the pertussis bacterium.

Table 6.2 High-risk Groups in Malaysia

*in accordance to Malaysian Maternal Immunisation Consensus Guidelines (2024)

Implication for Health Care Workers (HCWs)

Regardless of age, all HCWs should receive a single dose of Tdap, as soon as feasible, if they have not previously received it. Tdap can be administered regardless of the interval since the last tetanus- or diphtheria-containing vaccine. Td boosters are advocated every 10 years thereafter.

Evidence of Safety & Effectiveness

Childhood immunisation provides protection against diphtheria, but immunity wanes with age. By middle age, about half of those not revaccinated since childhood have antibody levels too low (<0.1 IU/ml) to ensure protection. A single booster dose in adults can restore protective levels within six weeks, but these antibodies also decline over time; about 25% lose protection within 2–6 years, and levels often return to near baseline by 5–6 years. This highlights the importance of regular booster doses to maintain protection and herd immunity.

References

  1. Centers for Disease Control and Prevention. (2020). Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: Updated recommendations of the Advisory Committee on Immunization Practices — United States, 2019. Morbidity and Mortality Weekly Report, 69(3), 77–83. https://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm
  2. Gao, H., Lau, E. H., & Cowling, B. J. (2022). Waning immunity after receipt of pertussis, diphtheria, tetanus, and polio-related vaccines: a systematic review and meta-analysis. The Journal of Infectious Diseases, 225(4), 557-566. https://1093/infdis/jiab480
  3. Havers, F. P., Moro, P. L., Hunter, P., Hariri, S., & Bernstein, H. (2020, January 24). Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: Updated recommendations of the Advisory Committee on Immunization Practices — United States, 2019. Morbidity and Mortality Weekly Report, 69(3), 77–83. https://doi.org/10.15585/mmwr.mm6903a5
  4. Obstetrical & Gynaecological Society of Malaysia. (2024). Malaysian Maternal Immunisation Consensus Guidelines. https://ogsm.org.my/docs/Maternal-Immunisation-Guidelines.pdf
  5. National Pharmaceutical Regulatory Agency (NPRA) Sistem Pendaftaran Produk & Perlesenan.https://quest3plus.bpfk.gov.my/pmo2/index.php
  6. World Health Organization. (2025). Diphtheria reported cases and incidence. https://immunizationdata.who.int/global/wiise-detail-page/diphtheria-reported-cases-and-incidence?CODE=MYS&YEAR=